18F-DCFPyL PET/CT 在前列腺癌生化复发早期病灶检测中的应用:248 例分析
该研究纳入 248 例生化复发前列腺癌患者,评估 18F-DCFPyL PET/CT 的病灶检出效能及其与 PSA 水平的关系。结果显示总阳性率为 86.3%,且随 PSA 升高而增加;即使 PSA<0.5 ng/ml 也有 59% 检出可疑复发灶。作者认为该显像可实现早期检出,检出效能与 68Ga-PSMA 及 18F-PSMA-1007 报道结果相当。
要点
- 248 例生化复发患者中 86.3% 的 18F-DCFPyL PET/CT 为阳性。
- PSA<0.5 ng/ml 时仍有 59%(17/29)检出可疑复发灶。
- 根治性前列腺切除术后 PSA<1.0 ng/ml 者中 39%–50% 检出前列腺窝外可疑病灶。
核心结论
- 18F-DCFPyL PET/CT 可在生化复发患者中实现早期病灶检出,即使 PSA 水平<0.5 ng/ml 也可检出。
- 其检出效能与 68Ga-PSMA 和 18F-PSMA-1007 的报道结果相当,对 PSA<2.0 ng/ml 患者可能优于 68Ga-PSMA。
研究设计与样本
- 研究纳入 2016 年 11 月至 2018 年间荷兰两家医院连续 248 例因生化复发接受 18F-DCFPyL PET/CT 扫描的患者。
- 患者既往接受根治性前列腺切除术(52%)、外照射放疗(42%)或近距离放疗(6%)。
- 显像在注射中位剂量 311 MBq 18F-DCFPyL 后 120 分钟进行。
主要发现
- 248 次 PET/CT 扫描中 214 次(86.3%)检出至少一个可疑癌症复发病灶(阳性扫描)。
- 扫描阳性率随 PSA 升高而增加:PSA<0.5 ng/ml 为 17/29(59%);0.5 至<1.0 ng/ml 为 20/29(69%);1.0 至<2.0 ng/ml 为 35/41(85%);2.0 至<5.0 ng/ml 为 69/73(95%);≥5.0 ng/ml 为 73/76(96%)。
- 在根治性前列腺切除术后 PSA<1.0 ng/ml 的患者(即挽救性放疗候选者)中,39%–50% 检出前列腺窝外可疑病灶。
关键数值与推荐
- 扫描阳性定义为至少一个提示癌症复发的可疑病灶。
- PSA<0.5 ng/ml 时扫描阳性率为 59%(17/29)。
- PSA 0.5 至<1.0 ng/ml 时扫描阳性率为 69%(20/29)。
- PSA 1.0 至<2.0 ng/ml 时扫描阳性率为 85%(35/41)。
- PSA 2.0 至<5.0 ng/ml 时扫描阳性率为 95%(69/73);PSA≥5.0 ng/ml 时为 96%(73/76)。
临床怎么用
- 对生化复发前列腺癌患者,18F-DCFPyL PET/CT 可在低 PSA 水平(包括<0.5 ng/ml)检出可疑复发灶,有助于早期定位。
- 根治性前列腺切除术后 PSA<1.0 ng/ml 的患者中,该显像可发现前列腺窝外可疑病灶,可能影响挽救性放疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate-specific membrane antigen (PSMA) PET/CT is increasingly used in patients with biochemically recurrent prostate cancer (BCR), mostly using gallium-68 (168Ga)-labelled radiotracers. Alternatively, fluorine-18 (18F)-labelled PSMA tracers are available, such as 18F-DCFPyL, which offer enhanced image quality and therefore potentially increased detection of small metastases. In this study we evaluate the lesion detection efficacy of 18F-DCFPyL PET/CT in patients with BCR and determine the detection efficacy as a function of their PSA value. METHODS: A total of 248 consecutive patients were evaluated and underwent scanning with 18F-DCFPyL PET/CT for BCR between November 2016 and 2018 in two hospitals in the Netherlands. Patients were examined after radical prostatectomy (52%), external-beam radiation therapy (42%) or brachytherapy (6%). Imaging was performed 120 min after injection of a median dose of 311 MBq 18F-DCFPyL. RESULTS: In 214 out of 248 PET/CT scans (86.3%), at least one lesion suggestive of cancer recurrence was detected ('positive scan'). Scan positivity increased with higher PSA values: 17/29 scans (59%) with PSA values <0.5 ng/ml; 20/29 (69%) with PSA 0.5 to <1.0 ng/ml; 35/41 (85%) with PSA 1.0 to <2.0 ng/ml; 69/73 (95%) with PSA 2.0 to <5.0 ng/ml; and 73/76 (96%) with PSA ≥5.0 ng/ml. Interestingly, suspicious lesions outside the prostatic fossa were detected in 39-50% of patients with PSA <1.0 ng/ml after radical prostatectomy (i.e. candidates for salvage radiotherapy). CONCLUSION: 18F-DCFPyL PET/CT offers early detection of lesions in patients with BCR, even at PSA levels <0.5 ng/ml. These results appear to be comparable to those reported for 68Ga-PSMA and 18F-PSMA-1007, with potentially increased detection efficacy compared to 68Ga-PSMA for patients with PSA <2.0.
引用
- Wondergem M, Jansen BHE, van der Zant FM, et al. Early lesion detection with 18F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2019. PMID: 31230088. doi:10.1007/s00259-019-04385-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。